Acumen shareholders back directors and equity plan
Acumen Pharmaceuticals, Inc. reported results of its 2026 annual stockholder meeting.
Rhea-AI Filing Summary
Acumen Pharmaceuticals, Inc. reported results of its 2026 annual stockholder meeting. Stockholders elected three Class II directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders also approved the Company’s Amended and Restated 2021 Equity Incentive Plan. Quorum was strong, with 57,051,456 of 72,227,580 shares outstanding, or approximately 78.99%, present or represented by proxy at the meeting.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding: 72,227,580 shares
Shares represented: 57,051,456 shares
Participation rate: 78.99%
+3 more
6 metrics
Shares outstanding
72,227,580 shares
Outstanding as of the record date for the 2026 annual meeting
Shares represented
57,051,456 shares
Present or represented by proxy at the 2026 annual meeting
Participation rate
78.99%
Percentage of outstanding shares represented at the annual meeting
Votes for auditor ratification
56,934,900 votes
For ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Equity plan approval votes
30,731,776 votes
Votes for approval of the Amended and Restated 2021 Equity Incentive Plan
Broker non-votes on equity plan
19,676,925 votes
Broker non-votes for the Amended and Restated 2021 Equity Incentive Plan proposal
Key Terms
Emerging growth company, Broker Non-Votes, Independent registered public accounting firm, Amended and Restated 2021 Equity Incentive Plan, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company x o Item 5.07 Submission of Matters to a Vote of Security Holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Broker Non-Votes financial
"Name | Votes For | Votes Withheld | Broker Non-Votes George Golumbeski, Ph.D."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Independent registered public accounting firm regulatory
"ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Amended and Restated 2021 Equity Incentive Plan financial
"The stockholders approved the Company’s Amended and Restated 2021 Equity Incentive Plan."
Annual meeting of stockholders financial
"held its 2026 annual meeting of stockholders (the “Annual Meeting”)."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Acumen Pharmaceuticals (ABOS) stockholders decide at the 2026 annual meeting?
Stockholders elected three Class II directors, ratified Ernst & Young LLP as auditor for 2026, and approved the Amended and Restated 2021 Equity Incentive Plan. These actions confirm board composition, external audit oversight, and continued use of equity-based compensation for employees and directors.
Which directors were elected at Acumen Pharmaceuticals’ 2026 annual meeting?
Stockholders elected George Golumbeski, Ph.D., Derrell Porter, M.D., and Laura Stoppel, Ph.D. as Class II directors. They will serve until the 2029 annual meeting of stockholders, and until their respective successors are elected and qualified, providing continuity on Acumen Pharmaceuticals’ board of directors.
Did Acumen Pharmaceuticals (ABOS) stockholders approve the Amended and Restated 2021 Equity Incentive Plan?
Yes, stockholders approved the Amended and Restated 2021 Equity Incentive Plan with 30,731,776 votes for, 6,618,621 against, 24,134 abstentions, and 19,676,925 broker non-votes. This approval permits Acumen to continue using equity awards as part of its compensation and incentive programs.
Who is Acumen Pharmaceuticals’ independent auditor for the year ending December 31, 2026?
Stockholders ratified the appointment of Ernst & Young LLP as Acumen Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 56,934,900 votes for, 113,074 against, and 3,482 abstentions, reflecting strong support for the auditor.
What were the vote totals for Acumen Pharmaceuticals’ Class II director elections?
For George Golumbeski, Ph.D., votes were 37,305,711 for and 68,820 withheld. For Derrell Porter, M.D., 30,926,494 for and 6,448,037 withheld. For Laura Stoppel, Ph.D., 30,812,559 for and 6,561,972 withheld. Each director election also had 19,676,925 broker non-votes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
